Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Operating Expenses (2016 - 2025)

Immucell's Operating Expenses history spans 16 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 34.29% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $9.8 million, up 2.24%, while the annual FY2025 figure was $9.8 million, 2.24% up from the prior year.
  • Operating Expenses reached $3.0 million in Q4 2025 per ICCC's latest filing, up from $2.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $3.0 million in Q4 2025 to a low of $1.9 million in Q2 2021.
  • Average Operating Expenses over 5 years is $2.4 million, with a median of $2.3 million recorded in 2023.
  • The largest YoY upside for Operating Expenses was 34.29% in 2025 against a maximum downside of 14.09% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $2.4 million in 2021, then grew by 8.72% to $2.6 million in 2022, then decreased by 6.66% to $2.5 million in 2023, then decreased by 9.82% to $2.2 million in 2024, then surged by 34.29% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Operating Expenses are $3.0 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025).